SSSarika Sharma

Sarika Sharma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarika Sharma has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ready to Eat Food: A Reason for Enhancement in Multidrug Resistance in Humans

    by Sheetal Negi, Sarika Sharma

    The increasing trend of consuming ready-to-eat (RTE) food has become a global phenomenon, and this has raised concerns about the potential negative impacts on human health. Recent studies have shown a correlation between the consumption of RTE foods and the expansion of multidrug resistance (MDR) in humans. MDR is a significant challenge in the effective theory of infectious diseases, as it limits the effectiveness of antibiotics and other drugs used in therapy. Consumption of RTE food contribute to the development of MDR in humans. Additionally, there are potential risks of consuming RTE food contaminated with antibiotic-resistant bacteria, which can cause severe health consequences. The article highlights the need for awareness campaigns on the potential hazard related to the ingestion of RTE food and the importance of responsible and safe food production practices. It also recommends the need for regulatory bodies to establish strict guidelines for the production and distribution of RTE food to ensure that they are free from harmful contaminants and that their consumption does not lead to the development of MDR in humans. Overall, this article provides a comprehensive analysis of the potential negative impacts of RTE food consumption on human health and emphasizes the need for a more cautious approach to food consumption to protect public health.


  • Open Access

    The medicinal plant Berberis aristata and its endophytes for pharmacological applications: Current research and future challenges

    by Sheetal Sharma, M. V. N. L. Chaitanya, Sarika Sharma, Sanjeev Kumar, Sarvesh Rustagi, Sangram Singh, Sheikh Shreaz, Ashutosh Kumar Rai, Rajeshwari Negi, Ajar Nath Yadav

    Exploring medicinal plants for their natural products to benefit humanity has been a practice since ancient times. Berberis aristata, also known as tree turmeric or Indian barberry, has a dominant spot in conventional medicine for 2500 plus years. In the latter years, this particular species has gained prime attention in pharmaceutical zone due to its scarcity. The plant and its formulations are used to treat numerous human health threats including cancer, diabetes, diarrhea, wound relieving, infections of eyes and ears, gynecological disorders, and HIV-AIDS. The bioactive compounds present in B. aristata are found to contain anti-inflammatory, antioxidant, and anti-microbial properties. The plant is critically jeopardized species of Indian Himalaya due to the collection of its roots at a large scale for obtaining berberine alkaloid and its conservation is of great concern. At present, isolation of endophytic entities from remedial plants revolutionized the path of discovering drugs from medicinal plants. Endophytes can produce the same bioactive as their host plant as well as another bioactive to address a variety of human health issues. The review examines the bioprospecting of B. aristata, a medicinal shrub from the family Berberidaceae, and its associated endophytes for the production of bioactive compounds with application to human health. Finally, the review provides a comprehensive outlook on the current status and future prospects of bioprospecting B. aristata and its endophytes to combat future human health threats is an exciting area of research that should be further explored.


  • Reconciling the Gap between Medications and their Potential Leads: The Role of Marine Metabolites in the Discovery of New Anticancer Drugs: A Comprehensive Review

    by Janvee Thaman, Rashmi Saxena Pal, Motamarri Venkata Naga Lalitha Chaitanya, Palakurthi Yanadaiah, Prabha Thangavelu, Sarika Sharma, Patrick Amoateng, Smriti Arora, Ponnusankar Sivasankaran, Pratibha Pandey, et al.

    One-third of people will be diagnosed with cancer at some point in their lives, making it the second leading cause of death globally each year after cardiovascular disease. The complex anticancer molecular mechanisms have been understood clearly with the advent of improved genomic, proteomic, and bioinformatics. Our understanding of the complex interplay between numerous genes and regulatory genetic components within cells explaining how this might lead to malignant phenotypes has greatly expanded. It was discovered that epigenetic resistance and a lack of multitargeting drugs were highlighted as major barriers to cancer treatment, spurring the search for innovative anticancer treatments. It was discovered that epigenetic resistance and a lack of multitargeting drugs were highlighted as major barriers to cancer treatment, spurring the search for innovative anticancer treatments. Many popular anticancer drugs, including irinotecan, vincristine, etoposide, and paclitaxel, have botanical origins. Actinomycin D and mitomycin C come from bacteria, while bleomycin and curacin come from marine creatures. However, there is a lack of research evaluating the potential of algae-based anticancer treatments, especially in terms of their molecular mechanisms. Despite increasing interest in the former, and the promise of the compounds to treat tumours that have been resistant to existing treatment, pharmaceutical development of these compounds has lagged. Thus, the current review focuses on the key algal sources that have been exploited as anticancer therapeutic leads, including their biological origins, phytochemistry, and the challenges involved in converting such leads into effective anticancer drugs.